Sign inJoin waitlistJoin the waitlist

Chitra Hosing

Medical Director of the Apheresis Center · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

Apheresis Center · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
1999–2000
Hematology and Medical Oncology
Baylor College of Medicine
1996–1999
Internal Medicine
New York Medical College
1993–1996
Medical Officer
1990–1993
University College Of Medical Sciences
1991
Jawaharlal Nehru Medical College
1988–1990
Doctor of Medicine
1986–1990
Lady Hardinge Medical College
1987
Lady Hardinge Medical College
1985

Research

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
New England Journal of Medicine · 2020 · 1,804 citations
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
Blood · 2009 · 655 citations
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Molecular Therapy · 2017 · 517 citations

Richard Champlin
256 papers
Uday Popat
198 papers
Muzaffar Qazilbash
161 papers
Elizabeth Shpall
159 papers
Partow Kebriaei
145 papers
Amin Alousi
134 papers · 3 as a fellow
Yago Nieto
124 papers
Issa Khouri
114 papers
Qaiser Bashir
98 papers · 1 as a fellow
Marcos de Lima
81 papers
Betul Oran
80 papers · 3 as a resident
PA
Paolo Anderlini
78 papers

Clinical trials

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Principal investigator · Not yet recruiting · Phase 2
M.D. Anderson Cancer Center
2027–2032
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2024–2030
Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2024–2027
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2024–2030